{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Dysphasia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}],"title":"alanine aminotransferase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"blurred vision"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"CK serum"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}],"title":"CPK increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"dysuria"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"floaters"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"musculoskeletal, connective tissue disorder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"myalgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"right ciliorecinal artery occlusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"rash acneiform"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"retinopathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"urinary tract infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"vision decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"weight gain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"ASPARTATE AMINOTRANSFERASE INCREASED"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"time from first dose to 30 days post last dose","groups":[{"description":"Toxicities with possible, or probable, or definite attribution to encorafenib or binimetinib, or both.\n\nTreatment Cohort 1 AA \\& GBM Treatment Cohort 2 anaplastic PXAs Treatment Cohort 3 Other Tumors","id":"OG000","title":"Patients Treated With Encorafenib or Binimetinib in All Cohorts"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Number of Participants With Adverse Events as Defined by Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}